Disease · MONDO_0044704
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| RT + Cisplatin vs RT + Cisplatin + Cetuximab: serious adverse events | 208 of 447 | 237 of 444 | 891 | NCT00265941 | Trial comparisons |
| Standard Fractionation RT + Cisplatin vs Accelerated Fractionation RT + Cisplatin: serious adverse events | 293 of 361 | 279 of 360 | 721 | NCT00047008 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: deaths from any cause | 86 of 348 | 62 of 344 | 692 | NCT02952586 | Trial comparisons |
| Avelumab + Standard of Care Chemotherapy (SOC CRT) vs Placebo + SOC CRT: serious adverse events | 184 of 348 | 177 of 344 | 692 | NCT02952586 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: deaths from any cause | 185 of 225 | 194 of 227 | 452 | NCT02347332 | Trial comparisons |
| Vinflunine Plus Methotrexate vs Methotrexate: serious adverse events | 106 of 225 | 81 of 227 | 452 | NCT02347332 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: deaths from any cause | 6 of 152 | 6 of 147 | 299 | NCT02254278 | Trial comparisons |
| IMRT 6 Weeks + Cisplatin vs IMRT 5 Weeks: serious adverse events | 31 of 152 | 11 of 147 | 299 | NCT02254278 | Trial comparisons |
| De-escalated Adjuvant Radiation Therapy (DART) vs Standard of Care Treatment (SOC): deaths from any cause | 2 of 136 | 9 of 92 | 228 | NCT02908477 | Trial comparisons |
| De-escalated Adjuvant Radiation Therapy (DART) vs Standard of Care Treatment (SOC): serious adverse events | 0 of 136 | 1 of 92 | 228 | NCT02908477 | Trial comparisons |
| Standard Treatment vs De-escalation Treatment: deaths from any cause | 2 of 49 | 1 of 36 | 85 | NCT03416153 | Trial comparisons |
| Standard Treatment vs De-escalation Treatment: serious adverse events | 5 of 49 | 3 of 36 | 85 | NCT03416153 | Trial comparisons |
| Cohort A: p16+ OPSCC vs Cohort B: p16- HNSCC: Tumor Response Rate (TRR) | 3 of 33 | 0 of 12 | 45 | NCT02369458 | Trial comparisons |
| Cohort A vs Cohort B: deaths from any cause | 1 of 7 | 1 of 12 | 19 | NCT00882583 | Trial comparisons |
| Cohort A vs Cohort B: serious adverse events | 1 of 7 | 5 of 12 | 19 | NCT00882583 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044704/comparisons